SDGR Schrödinger, Inc.
USHealthcareAs of 2026-07-10 14:27
Why SDGR matters now
Schrödinger, Inc. (SDGR) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.42 with -2.20% on the session and $1.23B in market capitalization; recent performance reads 1-month +31.44% and YTD -11.86%.
The latest financial table shown here is Q1 2026, with revenue of $58.6M, net income of $-60.0M, and EPS of $-0.81. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -12.6%.
The latest indexable market news headline is "AMD Is Up 150% This Year But Here Are 5 Overlooked Stocks Betting on What Comes Next" from 24/7 Wall Street.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.00; recent insider activity includes Farid Ramy filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.72
P/S
4.62
EV/EBITDA
-10.83
DCF Value
$-31.55
FCF Yield
-12.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
55.3%
Operating Margin
-64.7%
Net Margin
-40.6%
ROE
-30.8%
ROA
-16.3%
ROIC
-34.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $58.6M | $-60.0M | $-0.81 |
| Q4 2025 | $87.2M | $32.5M | $0.44 |
| FY 2025 | $255.9M | $-103.3M | $-1.41 |
| Q3 2025 | $54.3M | $-32.8M | $-0.45 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$18.00
Target (Median)
$18.00
Target Range
$18.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
1.64
Schrödinger, Inc., along with its affiliated entities, specializes in developing and deploying a sophisticated, physics-based software platform designed to accelerate the discovery of novel molecules. This technology finds application in both pharmaceutical development and various materials science endeavors. The company's operations are divided into two primary segments: Software and Drug Discovery. Within its Software division, Schrödinger focuses on marketing and licensing its specialized software. This software primarily serves drug discovery efforts within the life sciences industry, but also caters to clients in materials science sectors. Conversely, the Drug Discovery segment is dedicated to cultivating a portfolio of both preclinical and clinical programs. These initiatives are pursued both through internal research and development and via strategic collaborations. Schrödinger's global clientele spans biopharmaceutical companies, industrial enterprises, academic institutions, and government research laboratories worldwide. Founded in 1990, the company maintains its headquarters in New York, New York.